Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma

Cancer - United States
doi 10.1002/cncr.31706
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cost-Effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients With Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

Clinical Therapeutics
Pharmacology
2017English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

Daratumumab vs. Pomalidomide for the Treatment of Relapsed/Refractory Multiple Myeloma: A Cost‐effectiveness Analysis

American Journal of Hematology
Hematology
2018English

Enduring Efficacy and Tolerability of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma ( GEN 503): Final Results of an Open‐label, Phase 1/2 Study

British Journal of Haematology
Hematology
2019English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Cancer Science
Cancer ResearchMedicineOncology
2019English

Thalidomide Versus Dexamethasone for the Treatment of Relapsed and/or Refractory Multiple Myeloma: Results From OPTIMUM, a Randomized Trial

Haematologica
Hematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy